Lin M, Paik E, Mishra B, et al. Re-creating hereditary persistence of fetal hemoglobin (PHFH) with CRISPR/CAS9 to treat sickle cell disease (SCD) and beta-thalassemia (beta-thal). EHA 2017, abstract S147.
Etranacogene dezaparvovec bij hemofilie B: effectiviteit en veiligheid na 24 maanden
apr 2024 | Benigne hematologie